Findings
Digital health technologies often produce noisier data with additional sources of variation compared to traditional clinical trial settings.
There is a significant challenge in maintaining participant engagement and adherence in digital trials.
The need for pilot studies to address data flow, integration, and integrity is crucial.

Recommendations
Enhance participant engagement through hybrid approaches combining digital and traditional methods.
Conduct pilot studies to test data flow and integration before full-scale trials.
Refine data management guidelines based on experiences from digital trials like AHS.
Include diverse expertise in trial leadership, such as software engineers and biostatisticians.
Plan for comprehensive data analysis, including handling missing data.

Regulatory Considerations
Ensure data security, privacy, and integrity throughout the trial.
Develop a comprehensive plan for data analysis and management.
Consider the composition of the Data & Safety Monitoring Board to include diverse expertise.

Findings
Advantages of MCTs: Investigators highlighted remote data capture, access to real-time data for monitoring, and improved data quality as major benefits. They also noted reduced participant burden due to fewer in-person visits and increased participant engagement through real-time data access.
Challenges of MCTs: Increased site burden due to additional time required for technology setup, troubleshooting, and managing high data volumes was a common theme. Participants faced challenges such as technology unfamiliarity, device management, and potential behavior changes from real-time data access.
Support Needs: Investigators emphasized the need for technical support, staff training, and increased budgetary resources to manage devices and train participants. They also highlighted the importance of clear communication about device selection and capabilities from sponsors.

Recommendations
Sponsors should supply comprehensive device training, including hands-on and supplemental materials, and establish systems for ongoing technical support throughout the trial.
Include funds for device management, staff training, and participant support to accommodate the additional demands of MCTs.
Prioritize user-friendly devices to minimize participant burden and improve adherence.
Collaborate with investigators and participants during trial planning to ensure technologies align with study objectives and participant needs.
Focus on in-person, hands-on training to ensure staff and participants are comfortable with the technologies.

Regulatory Considerations
Devices must meet data security and safety requirements to address Institutional Review Board (IRB) concerns.
Provide detailed information about device safety, storage, and capabilities to ensure compliance with regulatory standards.
Clearly communicate data access levels to participants, minimizing risks of data misinterpretation.

Findings
Advantages of MCTs: Investigators highlighted streamlined study operations, remote data capture, and higher-quality, real-time data collection as key benefits. MCTs were also noted for their potential to reduce participant burden by enabling remote participation.
Challenges of MCTs: Investigators reported increased operational challenges, such as device setup, maintenance, and troubleshooting. They also noted time burdens for staff and uncertainties regarding data quality, including potential biases and technical malfunctions.
Support Needs: Investigators emphasized the need for technical support, comprehensive training for staff and participants, and adequate budgetary planning to address additional costs associated with MCTs.
Participant Considerations: While MCTs offer convenience and engagement opportunities for participants, challenges include the intrusiveness of data capture, technology adoption barriers, and potential negative impacts of real-time data access on participant behavior.
Recommendations: Investigators stressed the importance of collaborative relationships between sponsors and sites, user-friendly technology selection, and participant-centric trial designs.

Recommendations
Improve Training and Support: Sponsors should provide hands-on training for staff and participants, including troubleshooting support and device-specific materials.
Plan Budgets Appropriately: Include funds for device procurement, staff time, and technology management in trial budgets.
Enhance Technical Support: Sponsors should establish centralized technical support systems to address technology-related issues during trials.
Select Participant-Friendly Technologies: Prioritize devices that are intuitive, minimally intrusive, and suitable for the target population's needs.
Engage Stakeholders Early: Collaborate with investigators, participants, and sponsors during trial planning to align expectations and address potential challenges.

Regulatory Considerations
Data Security: Ensure data collected by mobile technologies comply with privacy and security regulations, and communicate these measures to IRBs.
Device Validation: Validate devices for the intended trial context to ensure reliability and minimize technical risks.
Participant Communication: Clearly inform participants about how their data will be used and provide transparency regarding data access.

Findings
There is a lack of research on patient perspectives regarding the use of digital health technologies in clinical trials.
Digital health technologies offer opportunities to reduce participant burden and streamline operations but require effective engagement strategies.
Protocols need to address safety signals and data contexts not covered by traditional designs.

Recommendations
Engage patients and research sites early and often in planning digital health trials.
Ensure that outcome measurements meaningful to patients are identified before selecting digital health technologies.
Conduct feasibility or pilot studies with representative patient populations prior to trial launch.
Provide thorough descriptions of digital health technologies in informed consent documents.
Ensure sites have appropriate infrastructure and training for digital health trials.

Regulatory Considerations
Protocols should address safety signals not previously observed with traditional designs.
Communicate clearly about data confidentiality risks to participants.
Ensure informed consent documents provide clear guidance on expectations and responsibilities.

Findings
The probability of receiving an irregular pulse notification was low, indicating a gap in detection sensitivity.
The study was not designed to assess the algorithm as a screening tool, highlighting a need for further research in this area.
The paroxysmal nature of atrial fibrillation presents challenges in interpreting notifications, suggesting a gap in understanding the condition's episodic nature.

Recommendations
Conduct further research to understand the implications of irregular pulse notifications.
Explore the potential for digital health technologies to engage users with healthcare systems.
Investigate the use of smartwatches and similar devices as population screening tools.
Develop methods to improve the accuracy and reliability of health monitoring algorithms.
Enhance user engagement and follow-up after receiving health notifications.

Regulatory Considerations
Ensure data privacy and consent in large-scale digital health studies.
Address the accuracy and reliability of health monitoring algorithms.
Consider the implications of using consumer-owned devices for health monitoring.